$1.32
11.15% yesterday
Nasdaq, Apr 03, 10:00 pm CET
ISIN
NL0015000DX5
Symbol
ATAI
Sector
Industry

ATAI Life Sciences N.V. Stock price

$1.32
-0.19 12.33% 1M
+0.26 24.06% 6M
-0.02 1.13% YTD
-1.08 44.98% 1Y
-4.00 75.24% 3Y
-18.14 93.24% 5Y
-18.14 93.24% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.17 11.15%
ISIN
NL0015000DX5
Symbol
ATAI
Sector
Industry

Key metrics

Market capitalization $260.77m
Enterprise Value $184.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 558.36
P/S ratio (TTM) P/S ratio 790.21
P/B ratio (TTM) P/B ratio 1.51
Revenue growth (TTM) Revenue growth -0.90%
Revenue (TTM) Revenue $330.00k
EBIT (operating result TTM) EBIT $-105.88m
Free Cash Flow (TTM) Free Cash Flow $-79.86m
Cash position $100.92m
EPS (TTM) EPS $-0.80
P/E forward negative
P/S forward 1,043.08
EV/Sales forward 737.04
Short interest 6.56%
Show more

Is ATAI Life Sciences N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

ATAI Life Sciences N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a ATAI Life Sciences N.V. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a ATAI Life Sciences N.V. forecast:

Buy
100%

Financial data from ATAI Life Sciences N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.33 0.33
0% 0%
100%
- Direct Costs 0.35 0.35
29% 29%
106%
-0.02 -0.02
88% 88%
-6%
- Selling and Administrative Expenses 55 55
7% 7%
16,724%
- Research and Development Expense 50 50
28% 28%
15,248%
-106 -106
18% 18%
-31,979%
- Depreciation and Amortization 0.35 0.35
29% 29%
106%
EBIT (Operating Income) EBIT -106 -106
18% 18%
-32,084%
Net Profit -129 -129
92% 92%
-38,970%

In millions USD.

Don't miss a Thing! We will send you all news about ATAI Life Sciences N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ATAI Life Sciences N.V. Stock News

Positive
Proactive Investors
6 days ago
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai's pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01.
Neutral
24/7 Wall Street
9 days ago
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations.
Positive
Proactive Investors
17 days ago
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and 2026, analysts at Jefferies have highlighted following the company's fourth quarter update.  “We see a catalyst-rich period with five-plus Phase 2/3 central nervous systems/neuro readouts in 2025 to 2026,” the analysts wrote in a note to clients.
More ATAI Life Sciences N.V. News

Company Profile

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Head office Netherlands
CEO Srinivas Rao
Employees 54
Founded 2018
Website www.atai.life

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today